Tag: securities laws

New York, June 26, 2025 (GLOBE NEWSWIRE) -- Kandal M Venture Limited (Nasdaq: FMFC) (the “Company”), a contract manufacturer of affordable luxury leather goods with manufacturing operations in Cambodia, today announced the closing of its initial public offering (the “Offering”) of 2,000,000 Class A ordinary shares (the “Class A Ordinary Shares”) at a public offering price of $4.00 per share (the “Offering Price”). The Class A Ordinary Shares began trading on the Nasdaq Capital Market on June 25, 2025, under the symbol “FMFC.”

CALGARY, ALBERTA, June 26, 2025 (GLOBE NEWSWIRE) -- Marksmen Energy Inc. ("Marksmen" or the "Company") is providing this announcement further to its news releases dated May 15 and 29, June 12 and 16, 2025, with respect to the Alberta Securities Commission ("ASC") having issued a management cease trade order ("MCTO") to Marksmen pursuant to its application under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") in respect of the default regarding the delay of the filing of its annual financial statements, accompanying management’s discussion and analysis and related chief executive officer ("CEO") and chief financial officer ("CFO") certifications for the financial year ended December 31, 2024 (collectively, the "Annual Filings").

GREENWICH, Conn., June 26, 2025 (GLOBE NEWSWIRE) -- Aetherium Acquisition (the “SPAC” or the “Company”), a publicly-traded special purpose acquisition company, today announced that its Special Meeting (“Meeting”), previously scheduled at 8:30 a.m. Eastern Time on June 27, 2025, has been postponed to 8:30 a.m. Eastern Time on July 7, 2025, and the redemption right deadline has been postponed to 5:00 p.m. Eastern Time on July 2, 2025.

CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the "Series C Warrants") and Series D warrants to purchase up to 20,000,000 shares of common stock (the "Series D Warrants"), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.